According to Facebook's filings, Mr. Hastings's only equity in Facebook prior to this purchase was 20, 000 restricted stock units he was granted when he joined the board in June 2011.
Most notably, we completed U.S. and Japanese filings for crizotinib in ALK-positive non-small cell lung cancer and U.S. and EU filings for axitinib in advanced renal cell carcinoma.